Mondelez stock reiterated Overweight at Morgan Stanley on earnings outlook By Investing.com

Morgan Stanley reiterated an Overweight rating on Mondelez and kept a $71 price target, about 14% above the $62.39 share price, while maintaining the stock as a Top Pick. The firm cited better visibility for above-consensus organic sales growth and cocoa cost deflation, which should drive positive EPS revisions into 2H 2026. Recent updates also included a $0.50 quarterly dividend, with peers raising targets on strong emerging-market performance.

Analysis

The market is starting to re-rate MDLZ as a quasi-defensive growth compounder, but the bigger insight is that margin expansion may now come from cost relief rather than pricing power. That matters because when commodity deflation replaces pricing as the earnings engine, the durability of forward EPS upgrades tends to improve: fewer demand-elasticity concerns, less risk of shelf-space pushback, and a cleaner path to estimate revision momentum into the next 2-4 quarters.

The underappreciated second-order effect is competitive. If cocoa and related inputs roll over faster than expected, large-scale branded snack players with global procurement and hedging sophistication should widen the gap versus regionals and private label, which often pass through costs later and more unevenly. That can support share gains in emerging markets and premium segments even if category volumes stay muted.

The main risk is that the valuation reset becomes too complacent about the pace of benefits. If freight/insurance pressures from geopolitical tensions offset part of the cocoa deflation, or if emerging-market FX weakens, the EPS upgrade story can flatten quickly into late 2025, especially after recent relative outperformance. Also, a shift to less frequent reporting would reduce short-term noise, but it could delay the market’s recognition of margin inflection rather than accelerate it if sell-side estimates remain conservative.

Net: this is a better medium-term than immediate catalyst trade. The cleanest setup is not chasing strength, but buying dips into any post-rally consolidation while the revision cycle is still early; if consensus starts converging toward management’s implied margin bridge, the stock can work another 8-12% before multiple expansion becomes the dominant driver.

Key Decisions for Investors

• Add to MDLZ on 3-5% pullbacks over the next 2-6 weeks; target 8-12% upside over 6-9 months as EPS revisions catch up, with downside contained if cocoa deflation proves sticky.
• Pair trade: long MDLZ / short a higher-cost, less diversified packaged food peer basket for 3-6 months; thesis is procurement scale and hedging discipline translate into faster margin expansion.
• Buy MDLZ Jan-2027 call spreads to express the medium-term re-rating without overpaying for near-term volatility; favorable if revisions accelerate into 2H26 as expected.
• Avoid chasing after any one-day strength spike; use strength to trim tactical exposure if implied revision momentum stalls for more than 1-2 quarters.